Utility of Comprehensive Serum Glycopeptide Spectra Analysis (CSGSA) for the Detection of Early Stage Epithelial Ovarian Cancer
Comprehensive serum glycopeptide spectra analysis (CSGSA) evaluates >10,000 serum glycopeptides and identifies unique glycopeptide peaks and patterns via supervised orthogonal partial least-squares discriminant modeling. CSGSA was more accurate than cancer antigen 125 (CA125) or human epididymis protein 4 (HE4) for detecting early stage epithelial ovarian cancer. Combined CSGSA, CA125, and HE4 had improved diagnostic performance. Thus, CSGSA may be a useful screening tool for detecting early stage epithelial ovarian cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Cancers - 12(2020), 9 vom: 21. Aug. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Matsuo, Koji [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 28.10.2020 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/cancers12092374 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM313994447 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM313994447 | ||
| 003 | DE-627 | ||
| 005 | 20231225151755.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers12092374 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1046.xml |
| 035 | |a (DE-627)NLM313994447 | ||
| 035 | |a (NLM)32825727 | ||
| 035 | |a (PII)E2374 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Matsuo, Koji |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Utility of Comprehensive Serum Glycopeptide Spectra Analysis (CSGSA) for the Detection of Early Stage Epithelial Ovarian Cancer |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.10.2020 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Comprehensive serum glycopeptide spectra analysis (CSGSA) evaluates >10,000 serum glycopeptides and identifies unique glycopeptide peaks and patterns via supervised orthogonal partial least-squares discriminant modeling. CSGSA was more accurate than cancer antigen 125 (CA125) or human epididymis protein 4 (HE4) for detecting early stage epithelial ovarian cancer. Combined CSGSA, CA125, and HE4 had improved diagnostic performance. Thus, CSGSA may be a useful screening tool for detecting early stage epithelial ovarian cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a cancer antigen 125 | |
| 650 | 4 | |a comprehensive serum glycopeptide spectra analysis | |
| 650 | 4 | |a epithelial ovarian cancer | |
| 650 | 4 | |a human epididymis protein 4 | |
| 650 | 4 | |a orthogonal partial least-squares discriminant analysis | |
| 650 | 4 | |a screening | |
| 700 | 1 | |a Tanabe, Kazuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Hayashi, Masaru |e verfasserin |4 aut | |
| 700 | 1 | |a Ikeda, Masae |e verfasserin |4 aut | |
| 700 | 1 | |a Yasaka, Miwa |e verfasserin |4 aut | |
| 700 | 1 | |a Machida, Hiroko |e verfasserin |4 aut | |
| 700 | 1 | |a Shida, Masako |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Kenji |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshida, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Hirasawa, Takeshi |e verfasserin |4 aut | |
| 700 | 1 | |a Imanishi, Tadashi |e verfasserin |4 aut | |
| 700 | 1 | |a Mikami, Mikio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d 2009 |g 12(2020), 9 vom: 21. Aug. |w (DE-627)NLM198667213 |x 2072-6694 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2020 |g number:9 |g day:21 |g month:08 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/cancers12092374 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2020 |e 9 |b 21 |c 08 | ||